# US 2026/0041649 A1 · Anti-inflammatory agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0041649 A1
- Document ID: US20260041649A1
- Status: Published application
- Kind: A1
- Application number: 19/150,047
- Filed: 2023-08-31
- Published: 2026-02-12
- Earliest claimed: 2023-01-25
- Assignees: Watanabe Oyster Laboratory Co., Ltd.
- Applicants: Watanabe Oyster Laboratory, Co., Ltd.
- Inventors: Mitsugu WATANABE
- Web page: https://patentgrep.com/patent/US20260041649A1

## CPC

- A61K 31/055: the aromatic ring being substituted by halogen
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

[Problem] The present invention demonstrates that, when added to the culture, DHMBA inhibits the proliferation of mouse inflammatory macrophage RAW264.7 cells, promotes their cell death, and reduces their cell number. It also demonstrates that DHMBA suppresses the increased production of inflammatory cytokines in RAW264.7 cells cultured with LPS, and in particular, DHMBA treatment suppresses osteoclast formation in RAW264.7 cells stimulated with LPS. Thus, the present invention provides a useful means of treating inflammatory diseases using DHMBA. [Solution] The present invention is characterized by having an anti-inflammatory effect by including 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient.

## Claims

### Claim 1

An anti-inflammatory agent comprising 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient, the agent having an anti-inflammatory effect.

### Claim 2

An inflammatory macrophage activity inhibitor comprising 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient, the inhibitor having an effect of suppressing activity of an inflammatory macrophage.

### Claim 3

A RAW264.7 cell proliferation inhibitor, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient, the inhibitor having an effect of suppressing proliferation of RAW264.7 cells.

### Claim 4

A proliferation inhibitor for RAW264.7 cells cultured with LPS, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient, the inhibitor having an effect of suppressing proliferation of RAW264.7 cells cultured with LPS.

### Claim 5

A RAW264.7 cell death promoter, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient, the promoter having an effect of promoting death of RAW264.7 cells.

### Claim 6

An inflammatory cytokine production inhibitor for RAW264.7 cells, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient, the inhibitor having an effect of suppressing inflammatory cytokine production in RAW264.7 cells.

### Claim 7

An inflammatory cytokine production inhibitor for RAW264.7 cells, comprising 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient, the inhibitor having an effect of suppressing inflammatory cytokine production in RAW264.7 cells.

### Claim 8

An osteoclast formation inhibitor for RAW264.7 cells, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient, the inhibitor having an effect of suppressing osteoclast formation in RAW264.7 cells.
